---
ticker: "IBB"
name: "iShares Biotechnology ETF"
url: "https://etf.net/etf/IBB"
grade: "A"
score: 73
graded_at: "2026-10-12"
category: "Biotech & Genomics"
category_rank: "4 of 17"
methodology: "https://etf.net/methodology"
---

# IBB: iShares Biotechnology ETF

Grade **A**, Score 73 of 100. Rank 4 of 17 in Biotech & Genomics.

Graded Oct 12, 2026.

## Grade pillars

| Pillar | Score | Category rank |
| --- | --- | --- |
| Cost | 69 | 6 of 17 |
| Mission | 83 | 6 of 9 |
| Risk | 61 | 8 of 17 |
| Tradability | 93 | 2 of 17 |
| Holdings | 46 | 13 of 17 |
| Durability | 89 | 1 of 17 |

## Top holdings

The fund holds 244 positions. These are the largest 30, by weight.

| # | Ticker | Name | Weight |
| --- | --- | --- | --- |
| 1 | GILD | Gilead Sciences | 8.36% |
| 2 | AMGN | Amgen Inc | 7.81% |
| 3 | VRTX | Vertex Pharmaceuticals | 7.58% |
| 4 | MRNA | Moderna | 5.89% |
| 5 | REGN | Regeneron Pharmaceuticals | 5.30% |
| 6 | NTRA | Natera | 3.86% |
| 7 | ARGX | Argenx SE Adr | 3.28% |
| 8 | ILMN | Illumina Inc | 3.00% |
| 9 | RVMD | Revolution Medicines | 2.62% |
| 10 | BIIB | Biogen | 2.37% |
| 11 | ALNY | Alnylam Pharmaceuticals | 2.22% |
| 12 | ONC | Beone Medicines AG | 2.14% |
| 13 | UTHR | United Therapeutics | 1.63% |
| 14 | INCY | Incyte Corp | 1.62% |
| 15 | INSM | Insmed | 1.55% |
| 16 | GMAB | Genmab Sponsored Adr | 1.47% |
| 17 | ROIV | Roivant Sciences Ltd | 1.33% |
| 18 | EXEL | Exelixis Inc | 1.03% |
| 19 | NBIX | Neurocrine Biosciences | 1.03% |
| 20 | CRL | Charles River Laboratories Interna | 1.02% |
| 21 | ASND | Ascendis Pharma | 1.01% |
| 22 | MEDP | Medpace Holdings | 0.99% |
| 23 | HALO | Halozyme Therapeutics | 0.89% |
| 24 | BBIO | Bridgebio Pharma | 0.82% |
| 25 | TECH | Bio Techne | 0.81% |
| 26 | BMRN | Biomarin Pharmaceutical | 0.75% |
| 27 | PCVX | Vaxcyte | 0.74% |
| 28 | TWST | Twist Bioscience | 0.73% |
| 29 | MDGL | Madrigal Pharmaceuticals | 0.73% |
| 30 | TXG | 10X Genomics Class A | 0.67% |

Source: etf.net, https://etf.net/etf/IBB. Please cite the page URL.